WO2021086271A1 - Composition contenant un extrait de mûrier et procédé de production associé - Google Patents

Composition contenant un extrait de mûrier et procédé de production associé Download PDF

Info

Publication number
WO2021086271A1
WO2021086271A1 PCT/TH2019/000053 TH2019000053W WO2021086271A1 WO 2021086271 A1 WO2021086271 A1 WO 2021086271A1 TH 2019000053 W TH2019000053 W TH 2019000053W WO 2021086271 A1 WO2021086271 A1 WO 2021086271A1
Authority
WO
WIPO (PCT)
Prior art keywords
mulberry extract
composition containing
composition
hchf
diet
Prior art date
Application number
PCT/TH2019/000053
Other languages
English (en)
Inventor
Petoon MANEEPAIROJ
Original Assignee
Mark One Innovation Center Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mark One Innovation Center Company Limited filed Critical Mark One Innovation Center Company Limited
Priority to CN201980037598.2A priority Critical patent/CN113133307A/zh
Priority to PCT/TH2019/000053 priority patent/WO2021086271A1/fr
Priority to TW109137889A priority patent/TW202118504A/zh
Publication of WO2021086271A1 publication Critical patent/WO2021086271A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/385—Concentrates of non-alcoholic beverages
    • A23L2/39—Dry compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates, generally, to the field of the composition containing mulberry extract (Morns alba or Morus spp.) which the said composition can be used as tonic and/or adaptogenic agent; cognitive enhancer and reducing risks of liver diseases, peptic ulcers, metabolic syndromes, obesity and/or cardiovascular diseases.
  • mulberry extract Morns alba or Morus spp.
  • Morus spp., kno n as mulberry is a fast-growing small to medium-sized plant. The leaves are alternately arranged, simle and often lobed and serrated on the margin.
  • the taxonomy of Morus is complex with more than 150 published species names including Morus alba L., Morus australis Poir, Morus cathayana, Morus celtidifolia Kunth, Morus indica - L., Morus insignis, Morus japonica Audib, Morus liboensis S.S., Morus macroura, Morus mesozygia Stapf, Morus mongolica, Morus nigra L., Morus notabilis C.K. Schneid., Morus rubra L, Morus serrata, Roxb., Morus trilobata, Morus wittiorum Hand.-Mazz.
  • the mulberry fruits are multiple fruit, approximately 2-3 cm long. Immature fruits are usually white, green or pale yellow. In most species the fruits turn pink and then red while ripening, then dark purple or black. However, the fruits of the white-fruited cultivar are white when ripe.
  • Mulberry fruit color derives from anthocyanins which is water-soluble. Normally, anthocyanin content depends on climate and area of cultiva ion, and is especially high in tropical area.
  • the ripe fruits are edible and commonly consumed as fruit or juice. Leaves are also edible in the form of tea.
  • Morus spp. or mulberry extract are mostly in the field of cosmetics. Only a few reports have been found that the Morus spp. or mulberry extract are used as nutraceutical or functional ingredients or foods such as a composition comprising the crude extract of the fruit of Morus alba L having neuro-protective activity (WO 2004/006946 Al) or an edible products with thermostatic and cognitive effects (US 2012/0087997 Al) which indicates that the said edible products comprising a mulberry extract.
  • the prior inventions also includes the use of mulberry extract as an active ingredient in anorectic agent and air regulator for diet (US 2006/0222720 Al) and the use of mulberry extract as an ingredient in nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise (US 2007/0196508 Al) and the use of mulberry extract together with other medicinal plant extracts in chewing gum, confection, and other oral delivery vehicles containing a traditional Chinese medicine or extract thereof (US 2010/0104518 Al).
  • This invention is aimed to improve health benefit of the mulberry extract by combined with some additional compounds wherein the combination provides increasing efficiency of said compounds in terms of cognitive enhancing effect and reduces risks of liver diseases, peptic ulcers, metabolic syndromes, obesity and/or cardiovascular diseases.
  • the composition according to this invention is obtained from the process either not using organic solvents or extracted with water and alcohol wherein the said extract comprises of phenolic or flavonoid compounds including anthocyanins, gallic acid, rutin or combination thereof.
  • the composition according to this invention can be used as tonic and/or adaptogenic agent; cognitive enhancer and reducing the risks of liver diseases, peptic ulcers, metabolic syndromes, obesity and/or cardiovascular diseases.
  • the uses of the composition according to this invention can be in food, beverage, food supplement or health products in any forms.
  • Figure 1 illustrates that the light microscope of liver tissue sections was stained with hematoxylin and eosin (H&E) at 20X magnification.
  • F OVX-HCHF diet + MME 10 mg/kg BW
  • G OVX-HCHF diet + MME 50 mg/kg BW
  • H OVX-HCHF diet + MME 250 mg/kg BW.
  • ND normal diet
  • HCHF high carbohydrate high fat diet
  • Veh vehicle
  • OVX-HCHF ovariectomized plus high carbohydrate high fat diet
  • Iso the isoflavone at dose of 15 mg/kg BW
  • MME10, 50 and 250 the microencapsulated mulberry fruits extract at dose of 10, 50 and 250 mg/kg BW, respectively.
  • Figure 2 illustrates that the effect of various doses of MME on the relative density of NF- kB and TNF-a in liver tissue was detected by Western blotting (a) and quantitatively analyzed (b). The levels of b-actin were normalized against the level of NF-kB and TNF- ⁇ .
  • ND normal diet
  • HCHF high carbohydrate high fat diet
  • Veh vehicle
  • OVX-HCHF ovariectomized plus high carbohydrate high fat diet
  • Iso the isoflavone at dose of 15 mg/kg BW
  • MME 10, 50 and 250 the microencapsulated mulberry fruits extract at dose of 10, 50 and 250 mg/kg BW, respectively.
  • Figure 3 illustrates that the effect of various doses of MME on the relative density of DNMT-1 and PPAR- ⁇ in liver tissue was detected by Western blotting (a) and quantitatively analyzed (b). The levels of b-actin were normalized against the level of DNMT-1 and PPAR- ⁇ .
  • FIG. 5 illustrates a photograph of the effect of mulberry fruits on gastric inflammation of rats orally treated with vehicle or ranitidine or mulberry fruits powder.
  • A Control (Naive intact)
  • B Vehicle + stress
  • C Mulberry fruits 2 mg/kg BW + stress
  • D Mulberry fruits 10 mg/kg B W + stress
  • E Mulberry fruits 50 mg/kg BW + stress
  • F Ranitidine 50 mg/kg BW + stress
  • ND normal diet
  • HCHF high carbohydrate high fat diet
  • Veh vehicle
  • OVX-HCHF ovariectomized plus high carbohydrate high fat diet
  • Iso the isoflavone at dose of 15 mg/kg BW
  • L-car the L-camitine at dose of 250 mg/kg BW
  • MME10, 50 and 250 the microencapsulated mulberry fruits extract at dose of 10, 50 and 250 mg/kg BW, respectively.
  • Figure 7 illustrates that the effect of various doses of MME on the relative density of PPAR- ⁇ in adipose tissue was detected by Western blotting (a) and quantitatively analyzed (b). The levels of b-actin were normalized against the level of PPAR- ⁇ .
  • ND normal diet
  • HCHF high carbohydrate high fat diet
  • Veh vehicle
  • OVX-HCHF ovariectomized plus high carbohydrate high fat diet
  • Iso the isoflavone at dose of 15 mg/kg BW
  • L-car the L- c ami tine at dose of 250 mg/kg BW
  • MME 10 50 and 250: the microencapsulated mulberry fmits extract at dose of 10, 50 and 250 mg/kg BW, respectively.
  • Figure 8 illustrates that the light microscope of white adipose tissue at gonadal area were stained with hematoxylin and eosin (H&E) at 40X magnification.
  • H&E hematoxylin and eosin
  • Figure 9 illustrates that the light microscope of white adipose tissue at mesenteric area were stained with hematoxylin and eosin (H&E) at 40X magnification.
  • H OVX-HCHF diet + MME 250 mg/kg BW.
  • Figure 10 illustrates that the light microscope of white adipose tissue at retroperitoneal area were stained with hematoxylin and eosin (H&E) at 40X magnification.
  • F OVX- HCHF diet + MME 10 mg/kg BW
  • G OVX-HCHF diet + MME 50 mg/kg BW
  • H OVX-HCHF diet + MME 250 mg/kg BW.
  • Figure 11 illustrates that the light microscope of white adipose tissue at subcutaneous area were stained with hematoxylin and eosin (H&E) at 40X magnification.
  • G OVX-HCHF diet + MME 50 mg/kg BW
  • H OVX-HCHF diet + MME 250 mg/kg BW.
  • ND normal diet
  • HCHF high carbohydrate high fat diet
  • Veh vehicle
  • OVX-HCHF ovariectomized plus high carbohydrate high fat diet
  • Iso the isoflavone at dose of 15 mg/kg BW
  • L-car the L-camitine at dose of 250 mg/kg BW
  • MME10, 50 and 250 the microencapsulated mulberry fruits extract at dose of 10, 50 and 250 mg/kg BW, respectively.
  • ND normal diet
  • HCHF high carbohydrate high fat diet
  • Veh vehicle
  • OVX-HCHF ovariectomized plus high carbohydrate high fat diet
  • Iso the isoflavone at dose of 15 mg/kg BW
  • L-car the L- camitine at dose of 250 mg/kg BW
  • MME10, 50 and 250 the microencapsulated mulberry fruits extract at dose of 10, 50 and 250 mg/kg BW, respectively.
  • a composition containing mulberry extract comprises of at least a mulberry extract, a sweetener, and an additive wherein each composition contains the following amount:
  • Additive making 100% w/w of total amount wherein the additive can be chosen from Maltodextrin, bulking agent, stabilizing agent, anticaking agent, acidulant, gelling agent, artificial flavor, food coloring, water, and milk.
  • sample composition containing mulberry extract is not intended to limit the scope of one or more embodiment of the present invention.
  • the following examples are provided to show one certain embodiment of the invention. It will be understood by those skilled in the art that the present invention is not limited by the specific embodiment of the following examples:
  • a composition containing mulberry extract in the form of capsule comprises of a. Mulberry extract 1 -60% w/w b. Maltodextrin 19-60% w/w c. Stabilizing agent which can be chosen from Gum Arabic or Polydextrose 2-20% w/w
  • the composition containing mulberry extract in the form of capsule also comprises of bulking agent which can be chosen fr m cassava flour or lactose of 0.01-37% w/w or anticaking agent which can be chosen from magnesium stearate or silicon dioxide of 0.01-37% w/w.
  • a composition containing mulberry extract in the form of instant powder drink comprises of a. Mulberry extract 1-60% w/w b. Bulking agent 36-98% w/w c. Sweetener 0.9-3% w/w d. Acidulant 0.1-1% w/w
  • a composition containing mulberry extract in the form of gel drink comprises of a. Mulberry extract 1 -60% w/w b. Water 38-84% w/w c. Sweetener 0.9-12% w/w d. Gelling agent 1 -2% w/w e. Acidulant 0.1-1% w/w
  • a composition containing mulberry extract and milk in the form of powdered milk drink comprises of a. Mulberry extract 2-50% w/w b. Milk 47-97% w/w c. Sweetener 1-3% w/w
  • a composition containing mulberry extract and milk in the form of milky drink comprises of a. Mulberry extract 1-50% w/w b. Milk 20-87% w/w c. Sweetener 1 -6% w/w d. Maltodextrin 7-10% w/w e. Carrageenan 1-10% w/w with an addition of artificial flavor and/or food coloring.
  • a solvent which is preferably an organic solvent which can be chosen from either water or alcohol or combination thereof or it is obtained without using a solvent, e.g. supercritical fluid extraction which uses substance in a condition hen temperature and pressure are above a critical point, or microwave-assisted extraction, or ultrasonic extraction.
  • sample composition containing mulberry extract is not intended to limit the scope of one or more embodiment of the present invention.
  • the following examples are provided to show one certain embodiment of the invention. It will be understood by those skilled in the art that the present invention is not limited by the specific embodiment of the following examples:
  • This invention discloses the composition containing mulberry juice or concentrate or mulberry powder or extract wherein the said mulberry is obtained from mulberry leaves or fruits.
  • the mulberry leaves or fruits according to this invention can be derived from Morns alba L., Morus australis Poir, Morus cathayana, Morus celtidifolia Kunth, Morus indica - L., Morus insignis , Morus japonica Audib, Morus liboensis S.S. , Morus macroura, Morus mesozygia Stapf , Morus mongolica, Morus nigra L. , Morus notabilis C.K. Schneid., Morus rubra L, Morus s errata, Roxb. , Morus triloba ta, Morus wittiorum Hand.-Mazz.
  • the mulberry extract according to this invention comprises of phenolic or flavonoid compounds comprise of anthocyanins, gallic acid, rutin as sho n in Table 1.
  • the phenolic compounds and flavonoids content in the mulberry extract according to this invention is ranging from 0.1 to 1000 microgram GAE/g extract and the anthocyanins content is ranging from 100-1000 microgram/g extract.
  • the composition containing the mulberry extract according to this invention can be used as tonic and/or adaptogenic agent, cognitive enhancer and reducing the risks of liver diseases, peptic ulcers, metabolic syndromes, obesity and/or cardiovascular diseases.
  • the adaptogenicity property of the composition containing the mulberry extract according to this invention is caused by exerting the effect at multi-target organs including but not limited to the modifications of sympathetic effects, oxidative stress balances as shown in Tables 2 and 3.
  • aaa p-value ⁇ .001 respectively; compared to normal rats which received normal diet, bbb p-value ⁇ .001; compared to normal rats which received HCHF diet and vehicle and vehicle and *, **, *** p-value ⁇ .05, .01, .001 respectively; compared to OVX rats which received HCHF and vehicle.
  • ND normal diet; HCHF, high carbohydrate high fat diet; OVX-HCHF, ovariectomized plus high.
  • HCHF high carbohydrate high fat diet
  • OVX-HCHF ovariectomized plus high carbohydrate high fat diet
  • MME10 50 and 250, the microencapsulated mulberry fruits extract at dose of 10, 50 and 250 mg/kg BW.
  • composition containing the mulberry extract according to this invention can be used for preventing or reducing the risk of liver disease due to its biological activities as shown in Tables 4-6 and figure 1.
  • Table 4 Serum biochemical parameters
  • a ’ aa p-value ⁇ 05, .01 respectively; compared to control rats which received normal diet and vehicle, bb p-value ⁇ 01; compared to normal rats which received HCHF diet and vehicle and *, **, *** p-value ⁇ 05, .01, .001 respectively; compared to OVX rats which received HCHF and vehicle.
  • ND normal diet
  • HCHF high carbohydrate high fat diet
  • OVX+HCHF ovariectomized rats which received high carbohydrate high fat diet
  • MME10, 50 and 250 the microencapsulated mulberry fruits extract at doses of 10, 50 and 250 mg/kg BW.
  • ND normal diet
  • HCHF high carbohydrate high fat diet
  • OVX+HCHF ovariectomized rats which received high carbohydrate high fat diet
  • MME10, 50 and 250 the microencapsulated mulberry fruits extract at doses of 10, 50 and 250 mg/kg BW.
  • composition according to this invention for reducing risk of peptic ulcers by decreasing oxidative stress by the mulberry extract as shown in Figures 4 and 5 and Table 7.
  • composition according to this invention for reducing risk of metabolic syndrome by reducing of adipocytes, improving metabolic profiles, decreasing adiposity index, decreasing oxidative stress and suppressing proinflammatory cytokines i.e. NF- kB, TNF-alpha and/or modifying the functions of peroxisome proliferating activated receptors and suppressing pancreatic lipases by the mulberry extract as shown in Tables 8-9.
  • composition according to this invention for reducing risk of cardiovascular diseases by suppressing angiotensin converting enzymes and/or improving Atherogenic index caused by the mulberry extract as shown in Table 10.
  • MME microencapsulated mulberry fruits extract
  • ACE angiotensin converting enzymes
  • AI Atherogenic index
  • composition containing the mulberry extract according to this invention can be used for improving cognitive functions by enhancing cholinergic functions and/or decreasing oxidative stress status and/or neurogenesis and/or enhancing signal transduction via mitogen activated protein kinase (MAPK) in a brain as shown in Table 11.
  • MAPK mitogen activated protein kinase
  • composition according to this invention can be used in food, food products, beverages, milk or food supplement or health products wherein the food, beverage, milk or food supplement or health products can be in the form of tablet, capsule, effervescent granule or tablet, granule, powder, gel, jelly, gum, candy, spray, film, patch, cream, ointment, lotion or similar.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Botany (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Composition contenant un extrait de mûrier comprenant au moins un extrait de mûrier, un édulcorant et un additif, l'extrait de mûrier étant obtenu par une extraction de feuilles ou de fruits au moyen d'un solvant, par exemple de l'eau ou de l'alcool, ou obtenu par un procédé n'utilisant pas de solvant, par exemple une extraction par fluide supercritique ou une extraction assistée par micro-ondes, ou une extraction par ultrasons ; ledit extrait de mûrier se compose d'une substance essentielle telle que des composés phénoliques ou flavonoïdes comprenant des anthocyanines, de l'acide gallique, de la rutine ou une combinaison de ceux-ci, et il peut être mélangé avec des aliments, des boissons, des compléments alimentaires ou des produits de santé.
PCT/TH2019/000053 2019-10-31 2019-10-31 Composition contenant un extrait de mûrier et procédé de production associé WO2021086271A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201980037598.2A CN113133307A (zh) 2019-10-31 2019-10-31 包含桑提取物的组合物及其生产方法
PCT/TH2019/000053 WO2021086271A1 (fr) 2019-10-31 2019-10-31 Composition contenant un extrait de mûrier et procédé de production associé
TW109137889A TW202118504A (zh) 2019-10-31 2020-10-30 包含桑提取物的組合物及其生產方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TH2019/000053 WO2021086271A1 (fr) 2019-10-31 2019-10-31 Composition contenant un extrait de mûrier et procédé de production associé

Publications (1)

Publication Number Publication Date
WO2021086271A1 true WO2021086271A1 (fr) 2021-05-06

Family

ID=69326615

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TH2019/000053 WO2021086271A1 (fr) 2019-10-31 2019-10-31 Composition contenant un extrait de mûrier et procédé de production associé

Country Status (3)

Country Link
CN (1) CN113133307A (fr)
TW (1) TW202118504A (fr)
WO (1) WO2021086271A1 (fr)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006946A1 (fr) 2002-07-10 2004-01-22 Kyung Hee University Composition comprenant un extrait brut du fruit de morus alba l possedant une activite neuroprotectrice
US20060222720A1 (en) 2005-03-29 2006-10-05 Hiromichi Yamashita Anorectic agent and air regulator for diet
US20070196508A1 (en) 2006-02-23 2007-08-23 Heuer Marvin A Nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise
US20100104518A1 (en) 2006-10-11 2010-04-29 Cai Jianwei J Chewing gum, confection, and other oral delivery vehicles containing a traditional chinese medicine or extract thereof
CN101107953B (zh) * 2007-08-10 2010-05-19 游文龙 一种桑椹保健茶及其制备方法
US20120087997A1 (en) 2009-06-18 2012-04-12 Innosense Ltd. Edible products with thermostatic and cognitive effects
CN103315347B (zh) * 2013-07-04 2015-06-03 广东省农业科学院蚕业与农产品加工研究所 一种桑果功能运动饮料
WO2017097013A1 (fr) * 2015-12-10 2017-06-15 深圳市贝沃德克生物技术研究院有限公司 Boisson fonctionnelle entièrement naturelle permettant d'éliminer des dérivés réactifs de l'oxygène nuisibles de corps humains, et procédé de préparation associé
CN107691956A (zh) * 2017-09-27 2018-02-16 广西宜州市宜源桑杆菌业有限公司 一种桑叶饮料颗粒及其制作方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101780147A (zh) * 2010-03-12 2010-07-21 广西药用植物园制药厂 一种桑叶抗炎、降血糖提取物及其制剂的制备方法
WO2013078658A1 (fr) * 2011-12-01 2013-06-06 Nestec S.A. Baies de morus (mûres) et prévention des pics de glucose
JP6621463B2 (ja) * 2014-04-13 2019-12-18 マルマル インベストメント エスピー．ゼット オー．オー． 血糖値を低下させ、体重管理をするための健康食品組成物
CN106912920A (zh) * 2015-12-28 2017-07-04 天津中新药业研究中心 一种含有桑叶提取物的组合物及其用途
CN107637743A (zh) * 2017-09-28 2018-01-30 广州白云山星群(药业)股份有限公司 无糖型桑叶颗粒固体饮料及其制备方法

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006946A1 (fr) 2002-07-10 2004-01-22 Kyung Hee University Composition comprenant un extrait brut du fruit de morus alba l possedant une activite neuroprotectrice
US20060222720A1 (en) 2005-03-29 2006-10-05 Hiromichi Yamashita Anorectic agent and air regulator for diet
US20070196508A1 (en) 2006-02-23 2007-08-23 Heuer Marvin A Nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise
US20100104518A1 (en) 2006-10-11 2010-04-29 Cai Jianwei J Chewing gum, confection, and other oral delivery vehicles containing a traditional chinese medicine or extract thereof
CN101107953B (zh) * 2007-08-10 2010-05-19 游文龙 一种桑椹保健茶及其制备方法
US20120087997A1 (en) 2009-06-18 2012-04-12 Innosense Ltd. Edible products with thermostatic and cognitive effects
CN103315347B (zh) * 2013-07-04 2015-06-03 广东省农业科学院蚕业与农产品加工研究所 一种桑果功能运动饮料
WO2017097013A1 (fr) * 2015-12-10 2017-06-15 深圳市贝沃德克生物技术研究院有限公司 Boisson fonctionnelle entièrement naturelle permettant d'éliminer des dérivés réactifs de l'oxygène nuisibles de corps humains, et procédé de préparation associé
CN107691956A (zh) * 2017-09-27 2018-02-16 广西宜州市宜源桑杆菌业有限公司 一种桑叶饮料颗粒及其制作方法

Also Published As

Publication number Publication date
CN113133307A (zh) 2021-07-16
TW202118504A (zh) 2021-05-16

Similar Documents

Publication Publication Date Title
KR101200344B1 (ko) 혈당강하용 기능성 여주차의 제조방법
US20100136064A1 (en) Nutraceutical composition
KR101464337B1 (ko) 고욤나무 추출물을 유효성분으로 함유하는 항비만용 조성물
KR101312491B1 (ko) 혈당강하용 기능성 여주음료의 제조방법
Komes et al. Novel approach to the development of functional goat’s milk-based beverages using medicinal plant extracts in combination with high intensity ultrasound treatment
KR20150098525A (ko) 숙취해소 및 간 보호기능 개선용 건강기능성 조성물, 이를 포함하는 건강기능성 식품 및 식품첨가제
JP2012070726A (ja) バイオアベイラビリティを高めた美容食品用組成物
KR101690369B1 (ko) 여주 혼합 열수추출물을 유효성분으로 포함하는 항비만용 약학적 조성물 및 이의 제조방법
KR102150162B1 (ko) 인체 흡수형 진세노사이드가 증진된 활성산양삼 추출액을 포함하는 스틱형 용기용 액상 조성물 및 그 제조방법
US8895083B2 (en) Composition for the maintenance of blood sugar levels comprising cinnamon and ginseng
JP2010275288A (ja) 宿酔を予防及び改善する機能性組成物とこれを含む食品及び食品添加剤
Heirangkhongjam et al. Nutritional evaluation of Rhus chinensis Mill.(Heimang) and development of value added products
KR20170053536A (ko) 도라지를 유효성분으로 포함하는 기관지질환 및 고지혈증 예방 효능의 도라지 함유 음료 및 이의 제조방법
WO2021086271A1 (fr) Composition contenant un extrait de mûrier et procédé de production associé
KR20200053016A (ko) 붓기 제거에 효과가 있는 식물성 천연물의 혼합 추출물을 포함하는 당뇨병의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품
Azli et al. Nutritional, phytochemical, antioxidant activity and sensory attributes of herbal infusion from sukun (Artocarpus altilis) leaf
JP2008050301A (ja) 膵リパーゼ阻害剤
JP2007070263A (ja) 糖尿病予防用組成物
JP2004323439A (ja) 血液粘性改善用組成物
JP2021024858A (ja) 血圧降下用組成物
KR100903504B1 (ko) 비라칸사스 열매 추출물질을 포함하는 기능식품 및 체중 감소제
JP4768105B2 (ja) 経口組成物
KR20160139953A (ko) 엉겅퀴 꽃 추출물을 유효성분으로 함유하는 항비만 조성물
KR100560411B1 (ko) 녹차카테킨을 유효성분으로 포함하는 숙취해소제
Yangilar Determination of antioxidant capacity, citric acid, phenolic compounds, physicochemical and sensory properties of Pepino marmalade yogurts enriched with erythritol and amaranth flour at different concentrations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19842905

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19842905

Country of ref document: EP

Kind code of ref document: A1